#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


1-1	0-10	Functional	_
1-2	11-23	Connectivity	_
1-3	24-26	of	_
1-4	27-30	the	_
1-5	31-36	Raphe	_
1-6	37-43	Nuclei	_
1-7	44-45	:	_
1-8	46-50	Link	_
1-9	51-53	to	_
1-10	54-61	Tobacco	_
1-11	62-72	Withdrawal	_
1-12	73-75	in	_
1-13	76-83	Smokers	http://maven.renci.org/NeuroBridge/neurobridge#Person
1-14	84-92	Abstract	_
1-15	93-103	Background	_
1-16	104-112	Although	_
1-17	113-121	nicotine	_
1-18	122-128	alters	_
1-19	129-141	serotonergic	_
1-20	142-156	neurochemistry	_
1-21	157-158	,	_
1-22	159-167	clinical	_
1-23	168-174	trials	_
1-24	175-177	of	_
1-25	178-190	serotonergic	_
1-26	191-202	medications	_
1-27	203-206	for	_
1-28	207-214	smoking	_
1-29	215-224	cessation	_
1-30	225-229	have	_
1-31	230-238	provided	_
1-32	239-244	mixed	_
1-33	245-252	results	_
1-34	253-254	.	_

2-1	255-268	Understanding	_
2-2	269-272	the	_
2-3	273-277	role	_
2-4	278-280	of	_
2-5	281-293	serotonergic	_
2-6	294-305	dysfunction	_
2-7	306-308	in	_
2-8	309-316	tobacco	http://maven.renci.org/NeuroBridge/neurobridge#CurrentUse
2-9	317-320	use	http://maven.renci.org/NeuroBridge/neurobridge#CurrentUse
2-10	321-329	disorder	http://maven.renci.org/NeuroBridge/neurobridge#CurrentUse
2-11	330-333	may	_
2-12	334-341	advance	_
2-13	342-353	development	_
2-14	354-356	of	_
2-15	357-362	novel	_
2-16	363-380	pharmacotherapies	_
2-17	381-382	.	_

3-1	383-390	Methods	_
3-2	391-401	Functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-3	402-410	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-4	411-420	resonance	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-5	421-428	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-6	429-432	was	_
3-7	433-437	used	_
3-8	438-440	to	_
3-9	441-448	measure	_
3-10	449-462	resting-state	_
3-11	463-473	functional	_
3-12	474-486	connectivity	_
3-13	487-489	of	_
3-14	490-493	the	_
3-15	494-499	raphe	_
3-16	500-506	nuclei	_
3-17	507-509	as	_
3-18	510-512	an	_
3-19	513-522	indicator	_
3-20	523-525	of	_
3-21	526-538	serotonergic	_
3-22	539-547	function	_
3-23	548-549	.	_

4-1	550-562	Connectivity	_
4-2	563-565	of	_
4-3	566-569	the	_
4-4	570-576	dorsal	_
4-5	577-580	and	_
4-6	581-587	median	_
4-7	588-593	raphe	_
4-8	594-600	nuclei	_
4-9	601-604	was	_
4-10	605-613	compared	_
4-11	614-621	between	_
4-12	622-624	18	_
4-13	625-630	young	_
4-14	631-638	smokers	_
4-15	639-640	(	_
4-16	641-648	briefly	_
4-17	649-658	abstinent	_
4-18	659-660	,	_
4-19	661-664	~40	_
4-20	665-672	minutes	_
4-21	673-685	post-smoking	_
4-22	686-687	)	_
4-23	688-691	and	_
4-24	692-694	19	_
4-25	695-700	young	_
4-26	701-711	nonsmokers	_
4-27	712-713	(	_
4-28	714-719	16–21	_
4-29	720-725	years	_
4-30	726-729	old	_
4-31	730-731	)	_
4-32	732-733	;	_
4-33	734-746	connectivity	_
4-34	747-750	was	_
4-35	751-755	also	_
4-36	756-764	examined	_
4-37	765-767	in	_
4-38	768-769	a	_
4-39	770-778	separate	_
4-40	779-785	sample	_
4-41	786-788	of	_
4-42	789-808	overnight-abstinent	http://maven.renci.org/NeuroBridge/neurobridge#Abstinent
4-43	809-816	smokers	http://maven.renci.org/NeuroBridge/neurobridge#Abstinent
4-44	817-818	(	_
4-45	819-824	18–25	_
4-46	825-830	years	_
4-47	831-834	old	_
4-48	835-836	)	_
4-49	837-838	,	_
4-50	839-845	before	_
4-51	846-849	and	_
4-52	850-855	after	_
4-53	856-863	smoking	_
4-54	864-867	the	_
4-55	868-873	first	_
4-56	874-883	cigarette	_
4-57	884-886	of	_
4-58	887-890	the	_
4-59	891-894	day	_
4-60	895-896	.	_

5-1	897-910	Relationships	_
5-2	911-918	between	_
5-3	919-931	connectivity	_
5-4	932-934	of	_
5-5	935-938	the	_
5-6	939-944	raphe	_
5-7	945-951	nuclei	_
5-8	952-956	with	_
5-9	957-970	psychological	_
5-10	971-981	withdrawal	_
5-11	982-985	and	_
5-12	986-993	craving	_
5-13	994-998	were	_
5-14	999-1005	tested	_
5-15	1006-1008	in	_
5-16	1009-1016	smokers	http://maven.renci.org/NeuroBridge/neurobridge#Person
5-17	1017-1018	.	_

6-1	1019-1026	Results	_
6-2	1027-1039	Connectivity	_
6-3	1040-1042	of	_
6-4	1043-1046	the	_
6-5	1047-1053	median	_
6-6	1054-1059	raphe	_
6-7	1060-1067	nucleus	_
6-8	1068-1072	with	_
6-9	1073-1076	the	_
6-10	1077-1082	right	_
6-11	1083-1094	hippocampal	_
6-12	1095-1102	complex	_
6-13	1103-1106	was	_
6-14	1107-1113	weaker	_
6-15	1114-1116	in	_
6-16	1117-1124	smokers	http://maven.renci.org/NeuroBridge/neurobridge#Person
6-17	1125-1129	than	_
6-18	1130-1132	in	_
6-19	1133-1143	nonsmokers	http://maven.renci.org/NeuroBridge/neurobridge#QuestionnaireonSmokingUrges
6-20	1144-1147	and	_
6-21	1148-1151	was	_
6-22	1152-1162	negatively	_
6-23	1163-1173	correlated	_
6-24	1174-1178	with	_
6-25	1179-1192	psychological	_
6-26	1193-1203	withdrawal	_
6-27	1204-1206	in	_
6-28	1207-1214	smokers	http://maven.renci.org/NeuroBridge/neurobridge#Person
6-29	1215-1216	.	_

7-1	1217-1219	In	_
7-2	1220-1239	overnight-abstinent	http://maven.renci.org/NeuroBridge/neurobridge#Abstinent
7-3	1240-1247	smokers	http://maven.renci.org/NeuroBridge/neurobridge#Abstinent
7-4	1248-1249	,	_
7-5	1250-1257	smoking	_
7-6	1258-1267	increased	_
7-7	1268-1280	connectivity	_
7-8	1281-1283	of	_
7-9	1284-1287	the	_
7-10	1288-1294	median	_
7-11	1295-1300	raphe	_
7-12	1301-1308	nucleus	_
7-13	1309-1313	with	_
7-14	1314-1317	the	_
7-15	1318-1323	right	_
7-16	1324-1335	hippocampal	_
7-17	1336-1343	complex	_
7-18	1344-1345	,	_
7-19	1346-1349	and	_
7-20	1350-1353	the	_
7-21	1354-1362	increase	_
7-22	1363-1366	was	_
7-23	1367-1377	positively	_
7-24	1378-1388	correlated	_
7-25	1389-1393	with	_
7-26	1394-1397	the	_
7-27	1398-1406	decrease	_
7-28	1407-1409	in	_
7-29	1410-1423	psychological	_
7-30	1424-1434	withdrawal	_
7-31	1435-1436	.	_

8-1	1437-1448	Conclusions	_
8-2	1449-1455	Relief	_
8-3	1456-1458	of	_
8-4	1459-1469	withdrawal	_
8-5	1470-1473	due	_
8-6	1474-1476	to	_
8-7	1477-1484	smoking	_
8-8	1485-1487	is	_
8-9	1488-1499	potentially	_
8-10	1500-1506	linked	_
8-11	1507-1509	to	_
8-12	1510-1513	the	_
8-13	1514-1526	serotonergic	_
8-14	1527-1534	pathway	_
8-15	1535-1539	that	_
8-16	1540-1548	includes	_
8-17	1549-1552	the	_
8-18	1553-1559	median	_
8-19	1560-1565	raphe	_
8-20	1566-1573	nucleus	_
8-21	1574-1577	and	_
8-22	1578-1589	hippocampal	_
8-23	1590-1597	complex	_
8-24	1598-1599	.	_

9-1	1600-1605	These	_
9-2	1606-1613	results	_
9-3	1614-1621	suggest	_
9-4	1622-1626	that	_
9-5	1627-1639	serotonergic	_
9-6	1640-1651	medications	_
9-7	1652-1655	may	_
9-8	1656-1658	be	_
9-9	1659-1669	especially	_
9-10	1670-1680	beneficial	_
9-11	1681-1684	for	_
9-12	1685-1692	smokers	http://maven.renci.org/NeuroBridge/neurobridge#Person
9-13	1693-1696	who	_
9-14	1697-1704	endorse	_
9-15	1705-1711	strong	_
9-16	1712-1725	psychological	_
9-17	1726-1736	withdrawal	_
9-18	1737-1743	during	_
9-19	1744-1754	abstinence	_
9-20	1755-1759	from	_
9-21	1760-1767	smoking	_
9-22	1768-1769	.	_

10-1	1770-1777	Methods	http://maven.renci.org/NeuroBridge/neurobridge#DataCollectionMethod
10-2	1778-1790	Participants	_
10-3	1791-1794	and	http://maven.renci.org/NeuroBridge/neurobridge#PhysicalMeasurement
10-4	1795-1805	Procedures	_
10-5	1806-1811	Study	_
10-6	1812-1813	1	_
10-7	1814-1815	:	_
10-8	1816-1823	Smokers	http://maven.renci.org/NeuroBridge/neurobridge#Person
10-9	1824-1826	vs	_
10-10	1827-1837	Nonsmokers	http://maven.renci.org/NeuroBridge/neurobridge#QuestionnaireonSmokingUrges
10-11	1838-1843	Study	_
10-12	1844-1845	1	_
10-13	1846-1854	employed	_
10-14	1855-1856	a	_
10-15	1857-1873	between-subjects	_
10-16	1874-1880	design	_
10-17	1881-1882	.	_

11-1	1883-1895	Thirty-seven	_
11-2	1896-1908	participants	_
11-3	1909-1910	(	_
11-4	1911-1913	18	_
11-5	1914-1921	smokers	http://maven.renci.org/NeuroBridge/neurobridge#Person
11-6	1922-1923	,	_
11-7	1924-1926	19	_
11-8	1927-1937	nonsmokers	http://maven.renci.org/NeuroBridge/neurobridge#QuestionnaireonSmokingUrges
11-9	1938-1939	,	_
11-10	1940-1943	all	_
11-11	1944-1949	16–21	_
11-12	1950-1955	years	_
11-13	1956-1958	of	_
11-14	1959-1962	age	_
11-15	1963-1964	)	_
11-16	1965-1969	were	_
11-17	1970-1979	recruited	_
11-18	1980-1987	through	_
11-19	1988-1994	online	_
11-20	1995-2009	advertisements	_
11-21	2010-2011	.	_

12-1	2012-2014	At	_
12-2	2015-2017	an	_
12-3	2018-2024	intake	_
12-4	2025-2032	session	_
12-5	2033-2034	,	_
12-6	2035-2047	participants	_
12-7	2048-2052	gave	_
12-8	2053-2060	written	_
12-9	2061-2069	informed	_
12-10	2070-2077	consent	_
12-11	2078-2083	after	_
12-12	2084-2093	receiving	_
12-13	2094-2095	a	_
12-14	2096-2104	detailed	_
12-15	2105-2116	explanation	_
12-16	2117-2119	of	_
12-17	2120-2123	the	_
12-18	2124-2129	study	_
12-19	2130-2131	(	_
12-20	2132-2140	approved	_
12-21	2141-2143	by	_
12-22	2144-2147	the	_
12-23	2148-2152	UCLA	_
12-24	2153-2166	Institutional	_
12-25	2167-2173	Review	_
12-26	2174-2179	Board	_
12-27	2180-2181	;	_
12-28	2182-2185	IRB	_
12-29	2186-2187	#	_
12-30	2188-2197	10-000259	_
12-31	2198-2199	)	_
12-32	2200-2201	.	_

13-1	2202-2211	Exclusion	_
13-2	2212-2220	criteria	_
13-3	2221-2225	were	_
13-4	2226-2227	:	_
13-5	2228-2236	positive	_
13-6	2237-2242	urine	_
13-7	2243-2247	test	_
13-8	2248-2251	for	_
13-9	2252-2259	illicit	_
13-10	2260-2265	drugs	_
13-11	2266-2267	(	_
13-12	2268-2277	including	_
13-13	2278-2287	marijuana	_
13-14	2288-2289	)	_
13-15	2290-2291	,	_
13-16	2292-2297	using	_
13-17	2298-2300	an	_
13-18	2301-2313	Instant-View	_
13-19	2314-2325	immunoassay	_
13-20	2326-2331	urine	_
13-21	2332-2336	test	_
13-22	2337-2338	(	_
13-23	2339-2343	ALFA	_
13-24	2344-2354	Scientific	_
13-25	2355-2362	Designs	_
13-26	2363-2364	,	_
13-27	2365-2369	Inc.	_
13-28	2370-2371	)	_
13-29	2372-2373	,	_
13-30	2374-2385	self-report	_
13-31	2386-2388	of	_
13-32	2389-2398	marijuana	_
13-33	2399-2402	use	_
13-34	2403-2404	>	_
13-35	2405-2406	8	_
13-36	2407-2412	times	_
13-37	2413-2416	per	_
13-38	2417-2422	month	_
13-39	2423-2426	and	_
13-40	2427-2434	alcohol	_
13-41	2435-2438	use	_
13-42	2439-2440	>	_
13-43	2441-2442	5	_
13-44	2443-2447	days	_
13-45	2448-2451	per	_
13-46	2452-2457	month	_
13-47	2458-2459	,	_
13-48	2460-2463	any	_
13-49	2464-2468	Axis	_
13-50	2469-2470	I	_
13-51	2471-2482	psychiatric	_
13-52	2483-2491	disorder	_
13-53	2492-2493	,	_
13-54	2494-2503	including	_
13-55	2504-2511	current	_
13-56	2512-2516	drug	_
13-57	2517-2522	abuse	_
13-58	2523-2525	or	_
13-59	2526-2536	dependence	_
13-60	2537-2538	(	_
13-61	2539-2544	other	_
13-62	2545-2549	than	_
13-63	2550-2558	nicotine	_
13-64	2559-2569	dependence	_
13-65	2570-2573	for	_
13-66	2574-2579	those	_
13-67	2580-2582	in	_
13-68	2583-2586	the	_
13-69	2587-2594	smoking	_
13-70	2595-2600	group	_
13-71	2601-2602	)	_
13-72	2603-2604	,	_
13-73	2605-2612	history	_
13-74	2613-2615	of	_
13-75	2616-2628	neurological	_
13-76	2629-2635	injury	_
13-77	2636-2638	or	_
13-78	2639-2646	disease	_
13-79	2647-2649	or	_
13-80	2650-2659	pregnancy	_
13-81	2660-2661	,	_
13-82	2662-2665	and	_
13-83	2666-2682	contraindication	_
13-84	2683-2686	for	_
13-85	2687-2690	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
13-86	2691-2699	scanning	_
13-87	2700-2701	(	_
13-88	2702-2706	e.g.	_
13-89	2707-2708	,	_
13-90	2709-2714	metal	_
13-91	2715-2723	material	_
13-92	2724-2728	such	_
13-93	2729-2731	as	_
13-94	2732-2740	implants	_
13-95	2741-2747	inside	_
13-96	2748-2751	the	_
13-97	2752-2756	body	_
13-98	2757-2758	)	_
13-99	2759-2760	.	_

14-1	2761-2769	Eighteen	_
14-2	2770-2782	participants	_
14-3	2783-2787	were	_
14-4	2788-2798	classified	_
14-5	2799-2801	as	_
14-6	2802-2809	smokers	http://maven.renci.org/NeuroBridge/neurobridge#Person
14-7	2810-2815	based	_
14-8	2816-2818	on	_
14-9	2819-2830	endorsement	_
14-10	2831-2833	of	_
14-11	2834-2839	daily	_
14-12	2840-2847	smoking	_
14-13	2848-2851	for	_
14-14	2852-2854	at	_
14-15	2855-2860	least	_
14-16	2861-2862	6	_
14-17	2863-2869	months	_
14-18	2870-2873	and	_
14-19	2874-2880	having	_
14-20	2881-2883	CO	_
14-21	2884-2898	concentrations	_
14-22	2899-2901	of	_
14-23	2902-2903	>	_
14-24	2904-2905	5	_
14-25	2906-2909	ppm	_
14-26	2910-2912	in	_
14-27	2913-2920	expired	_
14-28	2921-2924	air	_
14-29	2925-2926	(	_
14-30	2927-2938	Smokerlyzer	_
14-31	2939-2940	,	_
14-32	2941-2948	Bedfont	_
14-33	2949-2959	Scientific	_
14-34	2960-2961	)	_
14-35	2962-2963	.	_

15-1	2964-2967	All	_
15-2	2968-2975	smokers	http://maven.renci.org/NeuroBridge/neurobridge#Person
15-3	2976-2985	completed	_
15-4	2986-2989	the	_
15-5	2990-3000	Fagerström	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence
15-6	3001-3005	Test	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence
15-7	3006-3009	for	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence
15-8	3010-3018	Nicotine	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence
15-9	3019-3029	Dependence	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence
15-10	3030-3031	(	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence
15-11	3032-3036	FTND	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence
15-12	3037-3038	)	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence
15-13	3039-3041	at	_
15-14	3042-3045	the	_
15-15	3046-3052	intake	_
15-16	3053-3060	session	_
15-17	3061-3062	.	_

16-1	3063-3071	Nineteen	_
16-2	3072-3084	participants	_
16-3	3085-3089	were	_
16-4	3090-3100	classified	_
16-5	3101-3103	as	_
16-6	3104-3114	nonsmokers	_
16-7	3115-3116	,	_
16-8	3117-3124	because	_
16-9	3125-3129	they	_
16-10	3130-3138	endorsed	_
16-11	3139-3145	having	_
16-12	3146-3152	smoked	_
16-13	3153-3158	fewer	_
16-14	3159-3163	than	_
16-15	3164-3165	5	_
16-16	3166-3176	cigarettes	_
16-17	3177-3179	in	_
16-18	3180-3185	their	_
16-19	3186-3194	lifetime	_
16-20	3195-3198	and	_
16-21	3199-3202	had	_
16-22	3203-3205	CO	_
16-23	3206-3212	levels	_
16-24	3213-3215	of	_
16-25	3216-3217	<	_
16-26	3218-3219	5	_
16-27	3220-3223	ppm	_
16-28	3224-3226	in	_
16-29	3227-3234	expired	_
16-30	3235-3238	air	_
16-31	3239-3240	.	_

17-1	3241-3248	Testing	_
17-2	3249-3252	was	_
17-3	3253-3255	in	_
17-4	3256-3259	the	_
17-5	3260-3269	afternoon	_
17-6	3270-3271	,	_
17-7	3272-3275	and	_
17-8	3276-3288	participants	_
17-9	3289-3293	were	_
17-10	3294-3304	instructed	_
17-11	3305-3307	to	_
17-12	3308-3313	avoid	_
17-13	3314-3322	caffeine	_
17-14	3323-3326	for	_
17-15	3327-3328	2	_
17-16	3329-3334	hours	_
17-17	3335-3345	beforehand	_
17-18	3346-3347	.	_

18-1	3348-3355	Smokers	_
18-2	3356-3360	were	_
18-3	3361-3371	instructed	_
18-4	3372-3374	to	_
18-5	3375-3380	smoke	_
18-6	3381-3383	as	_
18-7	3384-3389	usual	_
18-8	3390-3395	until	_
18-9	3396-3398	30	_
18-10	3399-3406	minutes	_
18-11	3407-3413	before	_
18-12	3414-3422	arriving	_
18-13	3423-3425	at	_
18-14	3426-3429	the	_
18-15	3430-3437	testing	_
18-16	3438-3442	site	_
18-17	3443-3445	to	_
18-18	3446-3454	minimize	_
18-19	3455-3458	the	_
18-20	3459-3466	effects	_
18-21	3467-3469	of	_
18-22	3470-3478	nicotine	_
18-23	3479-3482	and	_
18-24	3483-3493	abstinence	_
18-25	3494-3496	on	_
18-26	3497-3510	resting-state	_
18-27	3511-3521	functional	_
18-28	3522-3534	connectivity	_
18-29	3535-3536	;	_
18-30	3537-3544	smokers	_
18-31	3545-3551	report	_
18-32	3552-3556	only	_
18-33	3557-3566	minimally	_
18-34	3567-3568	(	_
18-35	3569-3575	albeit	_
18-36	3576-3589	significantly	_
18-37	3590-3591	)	_
18-38	3592-3599	greater	_
18-39	3600-3610	withdrawal	_
18-40	3611-3613	30	_
18-41	3614-3621	minutes	_
18-42	3622-3630	compared	_
18-43	3631-3633	to	_
18-44	3634-3635	<	_
18-45	3636-3637	1	_
18-46	3638-3644	minute	_
18-47	3645-3650	after	_
18-48	3651-3658	smoking	_
18-49	3659-3660	a	_
18-50	3661-3670	cigarette	_
18-51	3671-3672	.	_

19-1	3673-3675	At	_
19-2	3676-3679	the	_
19-3	3680-3689	beginning	_
19-4	3690-3692	of	_
19-5	3693-3696	the	_
19-6	3697-3704	testing	_
19-7	3705-3712	session	_
19-8	3713-3725	participants	_
19-9	3726-3735	completed	_
19-10	3736-3739	the	_
19-11	3740-3748	Shiffman	http://maven.renci.org/NeuroBridge/neurobridge#WisconsinSmokingWithdrawalScale
19-12	3749-3755	Jarvik	http://maven.renci.org/NeuroBridge/neurobridge#WisconsinSmokingWithdrawalScale
19-13	3756-3766	Withdrawal	http://maven.renci.org/NeuroBridge/neurobridge#WisconsinSmokingWithdrawalScale
19-14	3767-3772	Scale	http://maven.renci.org/NeuroBridge/neurobridge#WisconsinSmokingWithdrawalScale
19-15	3773-3774	(	http://maven.renci.org/NeuroBridge/neurobridge#WisconsinSmokingWithdrawalScale
19-16	3775-3779	SJWS	http://maven.renci.org/NeuroBridge/neurobridge#WisconsinSmokingWithdrawalScale
19-17	3780-3781	)	http://maven.renci.org/NeuroBridge/neurobridge#WisconsinSmokingWithdrawalScale
19-18	3782-3793	immediately	_
19-19	3794-3800	before	_
19-20	3801-3811	undergoing	_
19-21	3812-3815	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
19-22	3816-3824	scanning	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
19-23	3825-3830	while	_
19-24	3831-3833	in	_
19-25	3834-3837	the	_
19-26	3838-3845	resting	_
19-27	3846-3851	state	_
19-28	3852-3853	.	_

20-1	3854-3859	These	_
20-2	3860-3870	procedures	_
20-3	3871-3875	were	_
20-4	3876-3880	part	_
20-5	3881-3883	of	_
20-6	3884-3885	a	_
20-7	3886-3892	larger	_
20-8	3893-3900	testing	_
20-9	3901-3908	battery	_
20-10	3909-3910	(	_
20-11	3911-3915	data	_
20-12	3916-3918	to	_
20-13	3919-3921	be	_
20-14	3922-3930	reported	_
20-15	3931-3940	elsewhere	_
20-16	3941-3942	)	_
20-17	3943-3944	.	_

21-1	3945-3948	The	_
21-2	3949-3956	average	_
21-3	3957-3965	duration	_
21-4	3966-3968	of	_
21-5	3969-3979	abstinence	_
21-6	3980-3986	before	_
21-7	3987-3997	completing	_
21-8	3998-4001	the	_
21-9	4002-4007	first	_
21-10	4008-4015	testing	_
21-11	4016-4023	battery	_
21-12	4024-4025	(	_
21-13	4026-4040	questionnaires	_
21-14	4041-4042	)	_
21-15	4043-4046	was	_
21-16	4047-4052	41.56	_
21-17	4053-4060	minutes	_
21-18	4061-4062	(	_
21-19	4063-4071	SD=36.26	_
21-20	4072-4079	minutes	_
21-21	4080-4081	)	_
21-22	4082-4083	,	_
21-23	4084-4087	and	_
21-24	4088-4091	the	_
21-25	4092-4099	average	_
21-26	4100-4108	duration	_
21-27	4109-4111	of	_
21-28	4112-4122	abstinence	_
21-29	4123-4128	prior	_
21-30	4129-4131	to	_
21-31	4132-4135	the	_
21-32	4136-4143	resting	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
21-33	4144-4149	state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
21-34	4150-4153	MRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
21-35	4154-4158	scan	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
21-36	4159-4162	was	_
21-37	4163-4168	49.87	_
21-38	4169-4176	minutes	_
21-39	4177-4178	(	_
21-40	4179-4187	SD=41.22	_
21-41	4188-4195	minutes	_
21-42	4196-4197	)	_
21-43	4198-4199	.	_

22-1	4200-4203	For	_
22-2	4204-4205	a	_
22-3	4206-4214	timeline	_
22-4	4215-4217	of	_
22-5	4218-4223	Study	_
22-6	4224-4225	1	_
22-7	4226-4236	procedures	_
22-8	4237-4238	,	_
22-9	4239-4242	see	_
22-10	4243-4256	supplementary	_
22-11	4257-4263	Figure	_
22-12	4264-4265	1	_
22-13	4266-4267	.	_

23-1	4268-4273	Study	_
23-2	4274-4275	2	_
23-3	4276-4277	:	_
23-4	4278-4285	Effects	_
23-5	4286-4288	of	_
23-6	4289-4294	Acute	_
23-7	4295-4302	Smoking	_
23-8	4303-4308	Study	_
23-9	4309-4310	2	_
23-10	4311-4319	employed	_
23-11	4320-4321	a	_
23-12	4322-4337	within-subjects	_
23-13	4338-4344	design	_
23-14	4345-4346	.	_

24-1	4347-4358	Twenty-four	_
24-2	4359-4371	participants	_
24-3	4372-4376	were	_
24-4	4377-4386	recruited	_
24-5	4387-4394	through	_
24-6	4395-4401	online	_
24-7	4402-4405	and	_
24-8	4406-4411	print	_
24-9	4412-4426	advertisements	_
24-10	4427-4428	.	_

25-1	4429-4431	At	_
25-2	4432-4434	an	_
25-3	4435-4442	initial	_
25-4	4443-4449	intake	_
25-5	4450-4457	session	_
25-6	4458-4459	,	_
25-7	4460-4472	participants	_
25-8	4473-4477	gave	_
25-9	4478-4485	written	_
25-10	4486-4494	informed	_
25-11	4495-4502	consent	_
25-12	4503-4508	after	_
25-13	4509-4518	receiving	_
25-14	4519-4520	a	_
25-15	4521-4529	detailed	_
25-16	4530-4541	explanation	_
25-17	4542-4544	of	_
25-18	4545-4548	the	_
25-19	4549-4554	study	_
25-20	4555-4556	(	_
25-21	4557-4565	approved	_
25-22	4566-4568	by	_
25-23	4569-4572	the	_
25-24	4573-4577	UCLA	_
25-25	4578-4591	Institutional	_
25-26	4592-4598	Review	_
25-27	4599-4604	Board	_
25-28	4605-4606	;	_
25-29	4607-4610	IRB	_
25-30	4611-4612	#	_
25-31	4613-4622	13-001240	_
25-32	4623-4624	)	_
25-33	4625-4626	.	_

26-1	4627-4636	Inclusion	_
26-2	4637-4645	criteria	_
26-3	4646-4650	were	_
26-4	4651-4652	:	_
26-5	4653-4655	18	_
26-6	4656-4658	to	_
26-7	4659-4661	25	_
26-8	4662-4667	years	_
26-9	4668-4670	of	_
26-10	4671-4674	age	_
26-11	4675-4678	and	_
26-12	4679-4686	smoking	_
26-13	4687-4689	at	_
26-14	4690-4695	least	_
26-15	4696-4697	5	_
26-16	4698-4708	cigarettes	_
26-17	4709-4712	per	_
26-18	4713-4716	day	_
26-19	4717-4720	for	_
26-20	4721-4723	at	_
26-21	4724-4729	least	_
26-22	4730-4731	1	_
26-23	4732-4736	year	_
26-24	4737-4738	.	_

27-1	4739-4748	Exclusion	_
27-2	4749-4757	criteria	_
27-3	4758-4762	were	_
27-4	4763-4764	:	_
27-5	4765-4773	positive	_
27-6	4774-4779	urine	_
27-7	4780-4784	test	_
27-8	4785-4788	for	_
27-9	4789-4796	illicit	_
27-10	4797-4802	drugs	_
27-11	4803-4804	(	_
27-12	4805-4814	including	_
27-13	4815-4824	marijuana	_
27-14	4825-4826	)	_
27-15	4827-4828	[	_
27-16	4829-4834	using	_
27-17	4835-4837	an	_
27-18	4838-4850	Instant-View	_
27-19	4851-4862	immunoassay	_
27-20	4863-4868	urine	_
27-21	4869-4873	test	_
27-22	4874-4875	(	_
27-23	4876-4880	ALFA	_
27-24	4881-4891	Scientific	_
27-25	4892-4899	Designs	_
27-26	4900-4901	,	_
27-27	4902-4906	Inc.	_
27-28	4907-4908	)	_
27-29	4909-4910	]	_
27-30	4911-4912	;	_
27-31	4913-4924	self-report	_
27-32	4925-4927	of	_
27-33	4928-4937	marijuana	_
27-34	4938-4941	use	_
27-35	4942-4943	>	_
27-36	4944-4945	8	_
27-37	4946-4951	times	_
27-38	4952-4955	per	_
27-39	4956-4961	month	_
27-40	4962-4965	and	_
27-41	4966-4973	alcohol	_
27-42	4974-4977	use	_
27-43	4978-4979	>	_
27-44	4980-4982	10	_
27-45	4983-4987	days	_
27-46	4988-4991	per	_
27-47	4992-4997	month	_
27-48	4998-4999	;	_
27-49	5000-5006	DSM-IV	_
27-50	5007-5018	psychiatric	_
27-51	5019-5028	disorders	_
27-52	5029-5038	including	_
27-53	5039-5048	substance	_
27-54	5049-5052	use	_
27-55	5053-5061	disorder	_
27-56	5062-5063	(	_
27-57	5064-5069	other	_
27-58	5070-5074	than	_
27-59	5075-5083	nicotine	_
27-60	5084-5094	dependence	_
27-61	5095-5096	)	_
27-62	5097-5098	;	_
27-63	5099-5106	history	_
27-64	5107-5109	of	_
27-65	5110-5122	neurological	_
27-66	5123-5129	injury	_
27-67	5130-5132	or	_
27-68	5133-5140	disease	_
27-69	5141-5142	,	_
27-70	5143-5152	pregnancy	_
27-71	5153-5154	,	_
27-72	5155-5157	or	_
27-73	5158-5161	use	_
27-74	5162-5164	of	_
27-75	5165-5176	mentholated	_
27-76	5177-5179	or	_
27-77	5180-5190	electronic	_
27-78	5191-5201	cigarettes	_
27-79	5202-5203	;	_
27-80	5204-5207	and	_
27-81	5208-5224	contraindication	_
27-82	5225-5228	for	_
27-83	5229-5232	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
27-84	5233-5241	scanning	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
27-85	5242-5243	.	_

28-1	5244-5248	Data	_
28-2	5249-5253	from	_
28-3	5254-5255	3	_
28-4	5256-5268	participants	_
28-5	5269-5273	with	_
28-6	5274-5283	excessive	_
28-7	5284-5288	head	_
28-8	5289-5295	motion	_
28-9	5296-5297	(	_
28-10	5298-5299	>	_
28-11	5300-5303	2.5	_
28-12	5304-5306	mm	_
28-13	5307-5318	translation	_
28-14	5319-5320	)	_
28-15	5321-5325	were	_
28-16	5326-5334	excluded	_
28-17	5335-5336	,	_
28-18	5337-5344	leaving	_
28-19	5345-5349	data	_
28-20	5350-5354	from	_
28-21	5355-5357	21	_
28-22	5358-5370	participants	_
28-23	5371-5374	for	_
28-24	5375-5384	inclusion	_
28-25	5385-5387	in	_
28-26	5388-5391	the	_
28-27	5392-5397	final	_
28-28	5398-5406	analyses	_
28-29	5407-5408	.	_

29-1	5409-5412	All	_
29-2	5413-5425	participants	_
29-3	5426-5430	were	_
29-4	5431-5437	tested	_
29-5	5438-5440	in	_
29-6	5441-5444	the	_
29-7	5445-5452	morning	_
29-8	5453-5458	after	_
29-9	5459-5468	overnight	_
29-10	5469-5470	(	_
29-11	5471-5474	~12	_
29-12	5475-5480	hours	_
29-13	5481-5482	)	_
29-14	5483-5493	abstinence	_
29-15	5494-5498	from	_
29-16	5499-5506	smoking	_
29-17	5507-5508	,	_
29-18	5509-5517	verified	_
29-19	5518-5520	by	_
29-20	5521-5530	measuring	_
29-21	5531-5533	CO	_
29-22	5534-5548	concentrations	_
29-23	5549-5551	in	_
29-24	5552-5559	expired	_
29-25	5560-5563	air	_
29-26	5564-5569	using	_
29-27	5570-5571	a	_
29-28	5572-5580	portable	_
29-29	5581-5588	monitor	_
29-30	5589-5590	(	_
29-31	5591-5597	coVita	_
29-32	5598-5599	)	_
29-33	5600-5601	,	_
29-34	5602-5605	and	_
29-35	5606-5611	again	_
29-36	5612-5623	immediately	_
29-37	5624-5629	after	_
29-38	5630-5637	smoking	_
29-39	5638-5641	one	_
29-40	5642-5651	cigarette	_
29-41	5652-5654	of	_
29-42	5655-5660	their	_
29-43	5661-5670	preferred	_
29-44	5671-5676	brand	_
29-45	5677-5678	.	_

30-1	5679-5681	In	_
30-2	5682-5686	each	_
30-3	5687-5689	of	_
30-4	5690-5693	the	_
30-5	5694-5695	2	_
30-6	5696-5703	testing	_
30-7	5704-5712	sessions	_
30-8	5713-5714	,	_
30-9	5715-5718	one	_
30-10	5719-5725	before	_
30-11	5726-5729	and	_
30-12	5730-5733	one	_
30-13	5734-5739	after	_
30-14	5740-5747	smoking	_
30-15	5748-5751	the	_
30-16	5752-5757	first	_
30-17	5758-5767	cigarette	_
30-18	5768-5770	of	_
30-19	5771-5774	the	_
30-20	5775-5778	day	_
30-21	5779-5780	,	_
30-22	5781-5793	participants	_
30-23	5794-5798	were	_
30-24	5799-5811	administered	_
30-25	5812-5815	the	_
30-26	5816-5820	SJWS	http://maven.renci.org/NeuroBridge/neurobridge#Thing
30-27	5821-5824	and	_
30-28	5825-5834	underwent	_
30-29	5835-5839	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
30-30	5840-5848	scanning	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
30-31	5849-5854	while	_
30-32	5855-5857	in	_
30-33	5858-5861	the	_
30-34	5862-5869	resting	_
30-35	5870-5875	state	_
30-36	5876-5877	.	_

31-1	5878-5883	These	_
31-2	5884-5894	procedures	_
31-3	5895-5899	were	_
31-4	5900-5904	part	_
31-5	5905-5907	of	_
31-6	5908-5909	a	_
31-7	5910-5916	larger	_
31-8	5917-5924	testing	_
31-9	5925-5932	battery	_
31-10	5933-5942	described	_
31-11	5943-5953	previously	_
31-12	5954-5955	.	_

32-1	5956-5959	The	_
32-2	5960-5967	average	_
32-3	5968-5972	time	_
32-4	5973-5980	between	_
32-5	5981-5984	the	_
32-6	5985-5989	pre-	_
32-7	5990-5993	and	_
32-8	5994-6006	post-smoking	_
32-9	6007-6012	scans	_
32-10	6013-6016	was	_
32-11	6017-6022	66.28	_
32-12	6023-6024	(	_
32-13	6025-6032	SD=8.49	_
32-14	6033-6034	)	_
32-15	6035-6042	minutes	_
32-16	6043-6044	,	_
32-17	6045-6048	and	_
32-18	6049-6052	the	_
32-19	6053-6060	average	_
32-20	6061-6065	time	_
32-21	6066-6073	between	_
32-22	6074-6081	smoking	_
32-23	6082-6085	and	_
32-24	6086-6089	the	_
32-25	6090-6102	post-smoking	_
32-26	6103-6107	scan	_
32-27	6108-6111	was	_
32-28	6112-6117	42.66	_
32-29	6118-6119	(	_
32-30	6120-6128	SD=12.15	_
32-31	6129-6130	)	_
32-32	6131-6138	minutes	_
32-33	6139-6140	.	_

33-1	6141-6143	At	_
33-2	6144-6147	the	_
33-3	6148-6157	beginning	_
33-4	6158-6160	of	_
33-5	6161-6164	the	_
33-6	6165-6171	intake	_
33-7	6172-6179	session	_
33-8	6180-6192	participants	_
33-9	6193-6197	also	_
33-10	6198-6207	completed	_
33-11	6208-6211	the	_
33-12	6212-6216	FTND	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence
33-13	6217-6218	.	_

34-1	6219-6222	For	_
34-2	6223-6224	a	_
34-3	6225-6233	timeline	_
34-4	6234-6236	of	_
34-5	6237-6242	Study	_
34-6	6243-6244	2	_
34-7	6245-6255	procedures	_
34-8	6256-6257	,	_
34-9	6258-6261	see	_
34-10	6262-6275	supplementary	_
34-11	6276-6282	Figure	_
34-12	6283-6284	2	_
34-13	6285-6286	.	_

35-1	6287-6294	Smokers	_
35-2	6295-6297	in	_
35-3	6298-6303	Study	_
35-4	6304-6305	1	_
35-5	6306-6310	were	_
35-6	6311-6312	,	_
35-7	6313-6315	on	_
35-8	6316-6323	average	_
35-9	6324-6325	,	_
35-10	6326-6339	significantly	_
35-11	6340-6347	younger	_
35-12	6348-6352	than	_
35-13	6353-6358	those	_
35-14	6359-6361	in	_
35-15	6362-6367	Study	_
35-16	6368-6369	2	_
35-17	6370-6371	(	_
35-18	6372-6373	F	_
35-19	6374-6375	(	_
35-20	6376-6380	1,56	_
35-21	6381-6382	)	_
35-22	6383-6390	=41.257	_
35-23	6391-6392	,	_
35-24	6393-6394	P	_
35-25	6395-6396	<	_
35-26	6397-6401	.001	_
35-27	6402-6403	)	_
35-28	6404-6405	.	_

36-1	6406-6410	They	_
36-2	6411-6415	also	_
36-3	6416-6419	had	_
36-4	6420-6428	slightly	_
36-5	6429-6434	lower	_
36-6	6435-6441	levels	_
36-7	6442-6444	of	_
36-8	6445-6453	nicotine	_
36-9	6454-6464	dependence	_
36-10	6465-6466	,	_
36-11	6467-6470	but	_
36-12	6471-6475	this	_
36-13	6476-6486	difference	_
36-14	6487-6490	was	_
36-15	6491-6494	not	_
36-16	6495-6508	statistically	_
36-17	6509-6520	significant	_
36-18	6521-6522	(	_
36-19	6523-6528	Study	_
36-20	6529-6530	1	_
36-21	6531-6535	mean	_
36-22	6536-6537	(	_
36-23	6538-6540	SD	_
36-24	6541-6542	)	_
36-25	6543-6544	:	_
36-26	6545-6549	2.56	_
36-27	6550-6551	(	_
36-28	6552-6556	2.38	_
36-29	6557-6558	)	_
36-30	6559-6560	;	_
36-31	6561-6566	Study	_
36-32	6567-6568	2	_
36-33	6569-6573	mean	_
36-34	6574-6575	(	_
36-35	6576-6578	SD	_
36-36	6579-6580	)	_
36-37	6581-6582	:	_
36-38	6583-6587	3.24	_
36-39	6588-6589	(	_
36-40	6590-6594	1.76	_
36-41	6595-6596	)	_
36-42	6597-6598	;	_
36-43	6599-6600	F	_
36-44	6601-6602	(	_
36-45	6603-6607	1,37	_
36-46	6608-6609	)	_
36-47	6610-6616	=1.056	_
36-48	6617-6618	,	_
36-49	6619-6625	P=.311	_
36-50	6626-6627	)	_
36-51	6628-6629	.	_

37-1	6630-6634	Both	_
37-2	6635-6642	Studies	_
37-3	6643-6646	The	_
37-4	6647-6660	Psychological	_
37-5	6661-6671	Withdrawal	_
37-6	6672-6675	and	_
37-7	6676-6683	Craving	_
37-8	6684-6693	subscales	_
37-9	6694-6696	of	_
37-10	6697-6700	the	_
37-11	6701-6705	SJWS	_
37-12	6706-6710	were	_
37-13	6711-6715	used	_
37-14	6716-6717	.	_

38-1	6718-6721	The	_
38-2	6722-6735	Psychological	_
38-3	6736-6746	Withdrawal	_
38-4	6747-6755	subscale	_
38-5	6756-6765	comprises	_
38-6	6766-6767	8	_
38-7	6768-6773	items	_
38-8	6774-6784	pertaining	_
38-9	6785-6787	to	_
38-10	6788-6791	the	_
38-11	6792-6801	affective	_
38-12	6802-6809	aspects	_
38-13	6810-6812	of	_
38-14	6813-6820	tobacco	_
38-15	6821-6831	withdrawal	_
38-16	6832-6833	,	_
38-17	6834-6837	and	_
38-18	6838-6841	the	_
38-19	6842-6849	Craving	_
38-20	6850-6858	subscale	_
38-21	6859-6868	comprises	_
38-22	6869-6870	7	_
38-23	6871-6876	items	_
38-24	6877-6878	.	_

39-1	6879-6886	Because	_
39-2	6887-6896	serotonin	_
39-3	6897-6908	dysfunction	_
39-4	6909-6911	is	_
39-5	6912-6922	associated	_
39-6	6923-6927	with	_
39-7	6928-6937	affective	_
39-8	6938-6947	disorders	_
39-9	6948-6949	(	_
39-10	6950-6954	e.g.	_
39-11	6955-6956	,	_
39-12	6957-6958	)	_
39-13	6959-6960	,	_
39-14	6961-6964	the	_
39-15	6965-6972	primary	_
39-16	6973-6981	analyses	_
39-17	6982-6991	pertained	_
39-18	6992-6994	to	_
39-19	6995-6999	data	_
39-20	7000-7004	from	_
39-21	7005-7008	the	_
39-22	7009-7022	Psychological	_
39-23	7023-7033	Withdrawal	_
39-24	7034-7042	subscale	_
39-25	7043-7044	;	_
39-26	7045-7049	data	_
39-27	7050-7054	from	_
39-28	7055-7058	the	_
39-29	7059-7066	Craving	_
39-30	7067-7075	subscale	_
39-31	7076-7080	were	_
39-32	7081-7085	used	_
39-33	7086-7088	in	_
39-34	7089-7098	secondary	_
39-35	7099-7107	analyses	_
39-36	7108-7115	because	_
39-37	7116-7118	of	_
39-38	7119-7122	the	_
39-39	7123-7133	importance	_
39-40	7134-7136	of	_
39-41	7137-7144	craving	_
39-42	7145-7147	to	_
39-43	7148-7155	relapse	_
39-44	7156-7157	(	_
39-45	7158-7162	e.g.	_
39-46	7163-7164	,	_
39-47	7165-7166	)	_
39-48	7167-7168	.	_

40-1	7169-7173	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
40-2	7174-7178	Data	_
40-3	7179-7190	Acquisition	_
40-4	7191-7195	Both	_
40-5	7196-7203	Studies	_
40-6	7204-7217	Resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
40-7	7218-7222	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
40-8	7223-7229	images	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
40-9	7230-7234	were	_
40-10	7235-7243	acquired	_
40-11	7244-7248	over	_
40-12	7249-7250	5	_
40-13	7251-7258	minutes	_
40-14	7259-7264	using	_
40-15	7265-7266	a	_
40-16	7267-7270	3-T	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
40-17	7271-7278	Siemens	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
40-18	7279-7281	AG	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
40-19	7282-7286	Trio	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
40-20	7287-7290	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
40-21	7291-7297	system	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
40-22	7298-7303	while	_
40-23	7304-7316	participants	_
40-24	7317-7323	viewed	_
40-25	7324-7325	a	_
40-26	7326-7331	black	_
40-27	7332-7338	screen	_
40-28	7339-7340	(	_
40-29	7341-7344	152	_
40-30	7345-7347	T2	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
40-31	7348-7349	*	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
40-32	7350-7359	-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
40-33	7360-7370	echoplanar	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
40-34	7371-7377	images	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
40-35	7378-7379	;	_
40-36	7380-7390	repetition	_
40-37	7391-7397	time=2	_
40-38	7398-7405	seconds	_
40-39	7406-7407	;	_
40-40	7408-7412	echo	_
40-41	7413-7420	time=30	_
40-42	7421-7433	milliseconds	_
40-43	7434-7435	;	_
40-44	7436-7441	slice	_
40-45	7442-7453	thickness=4	_
40-46	7454-7456	mm	_
40-47	7457-7458	;	_
40-48	7459-7463	flip	_
40-49	7464-7473	angle=90°	_
40-50	7474-7475	;	_
40-51	7476-7482	matrix	_
40-52	7483-7484	:	_
40-53	7485-7490	64×64	_
40-54	7491-7492	;	_
40-55	7493-7498	field	_
40-56	7499-7501	of	_
40-57	7502-7510	view=192	_
40-58	7511-7513	mm	_
40-59	7514-7515	)	_
40-60	7516-7517	.	_

41-1	7518-7521	For	_
41-2	7522-7527	Study	_
41-3	7528-7529	1	_
41-4	7530-7531	a	_
41-5	7532-7542	12-channel	_
41-6	7543-7552	head-coil	_
41-7	7553-7556	was	_
41-8	7557-7561	used	_
41-9	7562-7563	,	_
41-10	7564-7567	and	_
41-11	7568-7569	a	_
41-12	7570-7580	32-channel	_
41-13	7581-7585	head	_
41-14	7586-7590	coil	_
41-15	7591-7594	was	_
41-16	7595-7599	used	_
41-17	7600-7603	for	_
41-18	7604-7609	Study	_
41-19	7610-7611	2	_
41-20	7612-7613	.	_

42-1	7614-7616	In	_
42-2	7617-7621	both	_
42-3	7622-7629	studies	_
42-4	7630-7631	a	_
42-5	7632-7643	T2-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging
42-6	7644-7661	matched-bandwidth	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging
42-7	7662-7672	anatomical	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging
42-8	7673-7677	scan	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging
42-9	7678-7681	was	_
42-10	7682-7690	acquired	_
42-11	7691-7694	for	_
42-12	7695-7702	initial	_
42-13	7703-7715	registration	_
42-14	7716-7717	,	_
42-15	7718-7721	and	_
42-16	7722-7723	a	_
42-17	7724-7735	T1-weighted	http://maven.renci.org/NeuroBridge/neurobridge#DiffusionWeightedImaging
42-18	7736-7758	magnetization-prepared	http://maven.renci.org/NeuroBridge/neurobridge#DiffusionWeightedImaging
42-19	7759-7776	rapid-acquisition	http://maven.renci.org/NeuroBridge/neurobridge#DiffusionWeightedImaging
42-20	7777-7785	gradient	http://maven.renci.org/NeuroBridge/neurobridge#DiffusionWeightedImaging
42-21	7786-7790	echo	http://maven.renci.org/NeuroBridge/neurobridge#DiffusionWeightedImaging
42-22	7791-7792	(	http://maven.renci.org/NeuroBridge/neurobridge#DiffusionWeightedImaging
42-23	7793-7799	MPRAGE	http://maven.renci.org/NeuroBridge/neurobridge#DiffusionWeightedImaging
42-24	7800-7801	)	http://maven.renci.org/NeuroBridge/neurobridge#DiffusionWeightedImaging
42-25	7802-7806	scan	http://maven.renci.org/NeuroBridge/neurobridge#DiffusionWeightedImaging
42-26	7807-7810	was	_
42-27	7811-7819	acquired	_
42-28	7820-7823	for	_
42-29	7824-7831	further	_
42-30	7832-7844	registration	_
42-31	7845-7846	,	_
42-32	7847-7856	including	_
42-33	7857-7864	spatial	_
42-34	7865-7878	normalization	_
42-35	7879-7881	to	_
42-36	7882-7890	standard	_
42-37	7891-7896	space	_
42-38	7897-7898	(	_
42-39	7899-7907	Montreal	_
42-40	7908-7920	Neurological	_
42-41	7921-7930	Institute	_
42-42	7931-7932	[	_
42-43	7933-7936	MNI	_
42-44	7937-7938	]	_
42-45	7939-7940	)	_
42-46	7941-7942	.	_

43-1	7943-7947	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
43-2	7948-7952	Data	_
43-3	7953-7966	Preprocessing	_
43-4	7967-7972	Image	_
43-5	7973-7981	analysis	_
43-6	7982-7985	was	_
43-7	7986-7995	performed	_
43-8	7996-8001	using	_
43-9	8002-8005	the	_
43-10	8006-8011	FMRIB	_
43-11	8012-8020	Software	_
43-12	8021-8028	Library	_
43-13	8029-8030	(	_
43-14	8031-8034	FSL	_
43-15	8035-8036	)	_
43-16	8037-8044	version	_
43-17	8045-8050	5.0.9	_
43-18	8051-8052	(	_
43-19	8053-8075	www.fmrib.ox.ax.uk/fsl	_
43-20	8076-8077	)	_
43-21	8078-8079	.	_

44-1	8080-8083	The	_
44-2	8084-8089	image	_
44-3	8090-8101	time-course	_
44-4	8102-8104	of	_
44-5	8105-8108	the	_
44-6	8109-8116	resting	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
44-7	8117-8122	state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
44-8	8123-8127	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
44-9	8128-8132	data	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
44-10	8133-8136	was	_
44-11	8137-8142	first	_
44-12	8143-8152	realigned	_
44-13	8153-8155	to	_
44-14	8156-8166	compensate	_
44-15	8167-8170	for	_
44-16	8171-8176	small	_
44-17	8177-8181	head	_
44-18	8182-8191	movements	_
44-19	8192-8193	.	_

45-1	8194-8197	All	_
45-2	8198-8207	non-brain	_
45-3	8208-8214	matter	_
45-4	8215-8218	was	_
45-5	8219-8226	removed	_
45-6	8227-8232	using	_
45-7	8233-8236	FSL	_
45-8	8237-8238	’	_
45-9	8239-8240	s	_
45-10	8241-8246	brain	_
45-11	8247-8257	extraction	_
45-12	8258-8262	tool	_
45-13	8263-8264	.	_

46-1	8265-8276	Time-series	_
46-2	8277-8288	statistical	_
46-3	8289-8297	analysis	_
46-4	8298-8301	was	_
46-5	8302-8309	carried	_
46-6	8310-8313	out	_
46-7	8314-8319	using	_
46-8	8320-8325	FMRIB	_
46-9	8326-8327	’	_
46-10	8328-8329	s	_
46-11	8330-8338	Improved	_
46-12	8339-8345	Linear	_
46-13	8346-8351	Model	_
46-14	8352-8353	,	_
46-15	8354-8358	with	_
46-16	8359-8364	local	_
46-17	8365-8380	autocorrelation	_
46-18	8381-8391	correction	_
46-19	8392-8397	after	_
46-20	8398-8406	highpass	_
46-21	8407-8415	temporal	_
46-22	8416-8425	filtering	_
46-23	8426-8427	(	_
46-24	8428-8445	Gaussian-weighted	_
46-25	8446-8449	LSF	_
46-26	8450-8458	straight	_
46-27	8459-8463	line	_
46-28	8464-8471	fitting	_
46-29	8472-8473	,	_
46-30	8474-8478	with	_
46-31	8479-8487	sigma=50	_
46-32	8488-8495	seconds	_
46-33	8496-8497	)	_
46-34	8498-8499	.	_

47-1	8500-8502	No	_
47-2	8503-8515	participants	_
47-3	8516-8520	were	_
47-4	8521-8527	deemed	_
47-5	8528-8530	to	_
47-6	8531-8535	have	_
47-7	8536-8539	had	_
47-8	8540-8549	excessive	_
47-9	8550-8554	head	_
47-10	8555-8561	motion	_
47-11	8562-8563	(	_
47-12	8564-8565	>	_
47-13	8566-8569	2.5	_
47-14	8570-8572	mm	_
47-15	8573-8584	translation	_
47-16	8585-8586	)	_
47-17	8587-8588	.	_

48-1	8589-8592	For	_
48-2	8593-8597	both	_
48-3	8598-8605	studies	_
48-4	8606-8607	,	_
48-5	8608-8614	motion	_
48-6	8615-8623	cleaning	_
48-7	8624-8627	and	_
48-8	8628-8633	noise	_
48-9	8634-8643	reduction	_
48-10	8644-8648	were	_
48-11	8649-8658	performed	_
48-12	8659-8664	using	_
48-13	8665-8666	a	_
48-14	8667-8679	32-parameter	_
48-15	8680-8686	linear	_
48-16	8687-8697	regression	_
48-17	8698-8703	model	_
48-18	8704-8708	that	_
48-19	8709-8717	included	_
48-20	8718-8719	6	_
48-21	8720-8726	motion	_
48-22	8727-8737	parameters	_
48-23	8738-8739	(	_
48-24	8740-8741	3	_
48-25	8742-8755	translational	_
48-26	8756-8766	dimensions	_
48-27	8767-8772	along	_
48-28	8773-8774	x	_
48-29	8775-8776	,	_
48-30	8777-8778	y	_
48-31	8779-8780	,	_
48-32	8781-8784	and	_
48-33	8785-8786	z	_
48-34	8787-8791	axes	_
48-35	8792-8795	and	_
48-36	8796-8797	3	_
48-37	8798-8808	rotational	_
48-38	8809-8819	dimensions	_
48-39	8820-8821	:	_
48-40	8822-8823	“	_
48-41	8824-8829	pitch	_
48-42	8830-8831	”	_
48-43	8832-8833	,	_
48-44	8834-8835	“	_
48-45	8836-8840	roll	_
48-46	8841-8842	,	_
48-47	8843-8844	”	_
48-48	8845-8848	and	_
48-49	8849-8850	“	_
48-50	8851-8854	yaw	_
48-51	8855-8856	”	_
48-52	8857-8858	)	_
48-53	8859-8867	combined	_
48-54	8868-8872	with	_
48-55	8873-8876	the	_
48-56	8877-8887	timeseries	_
48-57	8888-8892	from	_
48-58	8893-8896	the	_
48-59	8897-8900	CSF	_
48-60	8901-8904	and	_
48-61	8905-8910	white	_
48-62	8911-8917	matter	_
48-63	8918-8920	to	_
48-64	8921-8928	provide	_
48-65	8929-8930	8	_
48-66	8931-8941	parameters	_
48-67	8942-8943	.	_

49-1	8944-8947	The	_
49-2	8948-8956	temporal	_
49-3	8957-8968	derivatives	_
49-4	8969-8971	of	_
49-5	8972-8977	these	_
49-6	8978-8988	parameters	_
49-7	8989-8992	and	_
49-8	8993-8996	the	_
49-9	8997-9006	quadratic	_
49-10	9007-9009	of	_
49-11	9010-9013	all	_
49-12	9014-9024	parameters	_
49-13	9025-9033	resulted	_
49-14	9034-9036	in	_
49-15	9037-9039	32	_
49-16	9040-9050	parameters	_
49-17	9051-9052	.	_

50-1	9053-9055	In	_
50-2	9056-9064	addition	_
50-3	9065-9066	,	_
50-4	9067-9076	framewise	_
50-5	9077-9089	displacement	_
50-6	9090-9091	(	_
50-7	9092-9094	FD	_
50-8	9095-9096	)	_
50-9	9097-9100	was	_
50-10	9101-9111	determined	_
50-11	9112-9116	with	_
50-12	9117-9134	root-mean-squared	_
50-13	9135-9141	matrix	_
50-14	9142-9153	calculation	_
50-15	9154-9155	(	_
50-16	9156-9161	using	_
50-17	9162-9165	FSL	_
50-18	9166-9167	’	_
50-19	9168-9169	s	_
50-20	9170-9171	‘	_
50-21	9172-9191	fsl_motion_outliers	_
50-22	9192-9193	’	_
50-23	9194-9198	tool	_
50-24	9199-9200	)	_
50-25	9201-9203	to	_
50-26	9204-9210	obtain	_
50-27	9211-9214	the	_
50-28	9215-9222	average	_
50-29	9223-9231	rotation	_
50-30	9232-9235	and	_
50-31	9236-9247	translation	_
50-32	9248-9257	parameter	_
50-33	9258-9269	differences	_
50-34	9270-9276	across	_
50-35	9277-9283	images	_
50-36	9284-9285	.	_

51-1	9286-9290	Time	_
51-2	9291-9297	points	_
51-3	9298-9302	that	_
51-4	9303-9311	exceeded	_
51-5	9312-9322	acceptable	_
51-6	9323-9325	FD	_
51-7	9326-9336	thresholds	_
51-8	9337-9341	were	_
51-9	9342-9350	included	_
51-10	9351-9353	as	_
51-11	9354-9355	“	_
51-12	9356-9361	spike	_
51-13	9362-9363	”	_
51-14	9364-9374	regressors	_
51-15	9375-9377	in	_
51-16	9378-9381	the	_
51-17	9382-9387	model	_
51-18	9388-9389	.	_

52-1	9390-9391	A	_
52-2	9392-9397	fixed	_
52-3	9398-9407	threshold	_
52-4	9408-9411	for	_
52-5	9412-9415	all	_
52-6	9416-9424	subjects	_
52-7	9425-9428	was	_
52-8	9429-9439	determined	_
52-9	9440-9442	by	_
52-10	9443-9454	calculating	_
52-11	9455-9458	the	_
52-12	9459-9461	SD	_
52-13	9462-9464	of	_
52-14	9465-9467	FD	_
52-15	9468-9474	across	_
52-16	9475-9478	all	_
52-17	9479-9483	data	_
52-18	9484-9487	and	_
52-19	9488-9497	computing	_
52-20	9498-9501	the	_
52-21	9502-9511	following	_
52-22	9512-9520	equation	_
52-23	9521-9522	:	_
52-24	9523-9527	0.25	_
52-25	9528-9532	mm+2	_
52-26	9533-9534	*	_
52-27	9535-9537	SD	_
52-28	9538-9539	.	_

53-1	9540-9543	The	_
53-2	9544-9548	time	_
53-3	9549-9555	series	_
53-4	9556-9558	of	_
53-5	9559-9562	the	_
53-6	9563-9572	resultant	_
53-7	9573-9582	residuals	_
53-8	9583-9587	from	_
53-9	9588-9591	the	_
53-10	9592-9602	regression	_
53-11	9603-9608	model	_
53-12	9609-9612	was	_
53-13	9613-9617	then	_
53-14	9618-9624	scaled	_
53-15	9625-9628	and	_
53-16	9629-9639	normalized	_
53-17	9640-9642	at	_
53-18	9643-9647	each	_
53-19	9648-9653	voxel	_
53-20	9654-9655	:	_
53-21	9656-9657	[	_
53-22	9658-9659	(	_
53-23	9660-9669	residuals	_
53-24	9670-9671	-	_
53-25	9672-9676	mean	_
53-26	9677-9678	)	_
53-27	9679-9682	/SD	_
53-28	9683-9684	]	_
53-29	9685-9689	+100	_
53-30	9690-9691	.	_

54-1	9692-9693	A	_
54-2	9694-9704	seed-based	_
54-3	9705-9713	approach	_
54-4	9714-9717	was	_
54-5	9718-9722	used	_
54-6	9723-9727	with	_
54-7	9728-9734	dorsal	_
54-8	9735-9738	and	_
54-9	9739-9745	median	_
54-10	9746-9751	raphe	_
54-11	9752-9758	nuclei	_
54-12	9759-9764	masks	_
54-13	9765-9772	created	_
54-14	9773-9776	and	_
54-15	9777-9785	provided	_
54-16	9786-9788	by	_
54-17	9789-9792	the	_
54-18	9793-9800	authors	_
54-19	9801-9803	of	_
54-20	9804-9805	.	_

55-1	9806-9818	Specifically	_
55-2	9819-9820	,	_
55-3	9821-9826	these	_
55-4	9827-9832	masks	_
55-5	9833-9837	were	_
55-6	9838-9845	defined	_
55-7	9846-9848	at	_
55-8	9849-9852	the	_
55-9	9853-9867	single-subject	_
55-10	9868-9873	level	_
55-11	9874-9876	by	_
55-12	9877-9886	examining	_
55-13	9887-9888	[	_
55-14	9889-9892	11C	_
55-15	9893-9894	]	_
55-16	9895-9899	DASB	_
55-17	9900-9907	binding	_
55-18	9908-9909	(	_
55-19	9910-9912	to	_
55-20	9913-9920	measure	_
55-21	9921-9925	SERT	_
55-22	9926-9938	availability	_
55-23	9939-9940	)	_
55-24	9941-9946	using	_
55-25	9947-9950	PET	_
55-26	9951-9952	.	_

56-1	9953-9956	The	_
56-2	9957-9962	masks	_
56-3	9963-9967	were	_
56-4	9968-9979	transformed	_
56-5	9980-9984	into	_
56-6	9985-9993	standard	_
56-7	9994-9995	(	_
56-8	9996-9999	MNI	_
56-9	10000-10001	)	_
56-10	10002-10007	space	_
56-11	10008-10010	by	_
56-12	10011-10016	first	_
56-13	10017-10028	registering	_
56-14	10029-10033	each	_
56-15	10034-10041	subject	_
56-16	10042-10043	’	_
56-17	10044-10045	s	_
56-18	10046-10049	PET	_
56-19	10050-10055	image	_
56-20	10056-10058	to	_
56-21	10059-10064	their	_
56-22	10065-10075	structural	_
56-23	10076-10078	MR	_
56-24	10079-10084	image	_
56-25	10085-10086	(	_
56-26	10087-10091	both	_
56-27	10092-10094	in	_
56-28	10095-10101	native	_
56-29	10102-10107	space	_
56-30	10108-10109	)	_
56-31	10110-10115	using	_
56-32	10116-10126	Freesurfer	_
56-33	10127-10128	’	_
56-34	10129-10130	s	_
56-35	10131-10141	bbregister	_
56-36	10142-10143	(	_
56-37	10144-10149	https	_
56-38	10150-10151	:	_
56-39	10152-10198	//surfer.nmr.mgh.harvard.edu/fswiki/bbregister	_
56-40	10199-10200	)	_
56-41	10201-10202	,	_
56-42	10203-10207	then	_
56-43	10208-10210	by	_
56-44	10211-10222	registering	_
56-45	10223-10226	the	_
56-46	10227-10233	native	_
56-47	10234-10239	space	_
56-48	10240-10242	MR	_
56-49	10243-10248	image	_
56-50	10249-10251	to	_
56-51	10252-10260	standard	_
56-52	10261-10266	space	_
56-53	10267-10268	(	_
56-54	10269-10272	MNI	_
56-55	10273-10274	)	_
56-56	10275-10280	using	_
56-57	10281-10286	FLIRT	_
56-58	10287-10290	and	_
56-59	10291-10296	FNIRT	_
56-60	10297-10299	in	_
56-61	10300-10303	FSL	_
56-62	10304-10305	,	_
56-63	10306-10309	and	_
56-64	10310-10314	then	_
56-65	10315-10317	by	_
56-66	10318-10326	applying	_
56-67	10327-10330	the	_
56-68	10331-10340	resulting	_
56-69	10341-10355	transformation	_
56-70	10356-10364	matrices	_
56-71	10365-10370	using	_
56-72	10371-10372	a	_
56-73	10373-10374	“	_
56-74	10375-10382	nearest	_
56-75	10383-10391	neighbor	_
56-76	10392-10393	”	_
56-77	10394-10407	interpolation	_
56-78	10408-10410	to	_
56-79	10411-10416	bring	_
56-80	10417-10420	the	_
56-81	10421-10422	2	_
56-82	10423-10428	raphe	_
56-83	10429-10435	nuclei	_
56-84	10436-10441	seeds	_
56-85	10442-10446	into	_
56-86	10447-10450	MNI	_
56-87	10451-10456	space	_
56-88	10457-10458	.	_

57-1	10459-10464	These	_
57-2	10465-10470	masks	_
57-3	10471-10474	can	_
57-4	10475-10477	be	_
57-5	10478-10482	seen	_
57-6	10483-10485	in	_
57-7	10486-10487	(	_
57-8	10488-10501	supplementary	_
57-9	10502-10508	Figure	_
57-10	10509-10510	3	_
57-11	10511-10512	)	_
57-12	10513-10514	.	_

58-1	10515-10518	For	_
58-2	10519-10520	a	_
58-3	10521-10525	full	_
58-4	10526-10537	description	_
58-5	10538-10540	of	_
58-6	10541-10544	how	_
58-7	10545-10550	these	_
58-8	10551-10556	masks	_
58-9	10557-10561	were	_
58-10	10562-10569	defined	_
58-11	10570-10572	in	_
58-12	10573-10586	subject-space	_
58-13	10587-10588	,	_
58-14	10589-10592	see	_
58-15	10593-10594	.	_

59-1	10595-10598	The	_
59-2	10599-10613	center-of-mass	_
59-3	10614-10623	locations	_
59-4	10624-10625	(	_
59-5	10626-10628	in	_
59-6	10629-10632	MNI	_
59-7	10633-10638	space	_
59-8	10639-10640	)	_
59-9	10641-10645	were	_
59-10	10646-10649	x=0	_
59-11	10650-10651	,	_
59-12	10652-10657	y=-28	_
59-13	10658-10659	,	_
59-14	10660-10665	z=-12	_
59-15	10666-10669	for	_
59-16	10670-10673	the	_
59-17	10674-10680	dorsal	_
59-18	10681-10686	raphe	_
59-19	10687-10694	nucleus	_
59-20	10695-10696	,	_
59-21	10697-10700	and	_
59-22	10701-10704	x=0	_
59-23	10705-10706	,	_
59-24	10707-10712	y=-34	_
59-25	10713-10714	,	_
59-26	10715-10720	z=-20	_
59-27	10721-10724	for	_
59-28	10725-10728	the	_
59-29	10729-10735	median	_
59-30	10736-10741	raphe	_
59-31	10742-10749	nucleus	_
59-32	10750-10751	.	_

60-1	10752-10755	The	_
60-2	10756-10762	dorsal	_
60-3	10763-10768	raphe	_
60-4	10769-10773	seed	_
60-5	10774-10782	location	_
60-6	10783-10791	extended	_
60-7	10792-10796	from	_
60-8	10797-10800	x=4	_
60-9	10801-10803	to	_
60-10	10804-10806	-6	_
60-11	10807-10808	,	_
60-12	10809-10814	y=-32	_
60-13	10815-10817	to	_
60-14	10818-10821	-26	_
60-15	10822-10823	,	_
60-16	10824-10827	and	_
60-17	10828-10833	z=-18	_
60-18	10834-10836	to	_
60-19	10837-10840	-10	_
60-20	10841-10842	.	_

61-1	10843-10846	The	_
61-2	10847-10853	median	_
61-3	10854-10859	raphe	_
61-4	10860-10864	seed	_
61-5	10865-10873	location	_
61-6	10874-10882	extended	_
61-7	10883-10887	from	_
61-8	10888-10891	x=2	_
61-9	10892-10894	to	_
61-10	10895-10897	-6	_
61-11	10898-10899	,	_
61-12	10900-10905	y=-36	_
61-13	10906-10908	to	_
61-14	10909-10912	-30	_
61-15	10913-10914	,	_
61-16	10915-10918	and	_
61-17	10919-10924	z=-26	_
61-18	10925-10927	to	_
61-19	10928-10931	-18	_
61-20	10932-10933	.	_

62-1	10934-10942	Contrast	_
62-2	10943-10949	images	_
62-3	10950-10954	were	_
62-4	10955-10965	registered	_
62-5	10966-10973	through	_
62-6	10974-10975	a	_
62-7	10976-10982	3-step	_
62-8	10983-10992	procedure	_
62-9	10993-10994	;	_
62-10	10995-10998	EPI	_
62-11	10999-11005	images	_
62-12	11006-11010	were	_
62-13	11011-11016	first	_
62-14	11017-11027	registered	_
62-15	11028-11030	to	_
62-16	11031-11034	the	_
62-17	11035-11052	matched-bandwidth	_
62-18	11053-11068	high-resolution	_
62-19	11069-11079	structural	_
62-20	11080-11085	image	_
62-21	11086-11087	,	_
62-22	11088-11092	then	_
62-23	11093-11095	to	_
62-24	11096-11099	the	_
62-25	11100-11106	MPRAGE	_
62-26	11107-11117	structural	_
62-27	11118-11123	image	_
62-28	11124-11125	,	_
62-29	11126-11129	and	_
62-30	11130-11137	finally	_
62-31	11138-11142	into	_
62-32	11143-11151	standard	_
62-33	11152-11153	(	_
62-34	11154-11157	MNI	_
62-35	11158-11159	)	_
62-36	11160-11165	space	_
62-37	11166-11167	,	_
62-38	11168-11173	using	_
62-39	11174-11186	12-parameter	_
62-40	11187-11193	affine	_
62-41	11194-11209	transformations	_
62-42	11210-11211	.	_

63-1	11212-11224	Registration	_
63-2	11225-11229	from	_
63-3	11230-11236	MPRAGE	_
63-4	11237-11247	structural	_
63-5	11248-11254	images	_
63-6	11255-11257	to	_
63-7	11258-11266	standard	_
63-8	11267-11272	space	_
63-9	11273-11276	was	_
63-10	11277-11284	further	_
63-11	11285-11292	refined	_
63-12	11293-11298	using	_
63-13	11299-11304	FNIRT	_
63-14	11305-11314	nonlinear	_
63-15	11315-11327	registration	_
63-16	11328-11329	.	_

64-1	11330-11336	Images	_
64-2	11337-11341	were	_
64-3	11342-11350	smoothed	_
64-4	11351-11356	using	_
64-5	11357-11358	a	_
64-6	11359-11363	5-mm	_
64-7	11364-11374	full-width	_
64-8	11375-11377	at	_
64-9	11378-11390	half-maximum	_
64-10	11391-11399	Gaussian	_
64-11	11400-11406	kernel	_
64-12	11407-11408	.	_

65-1	11409-11418	Smoothing	_
65-2	11419-11422	was	_
65-3	11423-11432	performed	_
65-4	11433-11438	after	_
65-5	11439-11449	extraction	_
65-6	11450-11452	of	_
65-7	11453-11456	the	_
65-8	11457-11467	timeseries	_
65-9	11468-11472	data	_
65-10	11473-11479	within	_
65-11	11480-11483	the	_
65-12	11484-11490	dorsal	_
65-13	11491-11494	and	_
65-14	11495-11501	median	_
65-15	11502-11507	raphe	_
65-16	11508-11514	nuclei	_
65-17	11515-11517	to	_
65-18	11518-11523	avoid	_
65-19	11524-11527	the	_
65-20	11528-11537	inclusion	_
65-21	11538-11540	of	_
65-22	11541-11547	signal	_
65-23	11548-11552	from	_
65-24	11553-11564	surrounding	_
65-25	11565-11572	regions	_
65-26	11573-11575	in	_
65-27	11576-11588	higher-level	_
65-28	11589-11597	analyses	_
65-29	11598-11602	fMRI	_
65-30	11603-11607	Data	_
65-31	11608-11616	Analysis	_
65-32	11617-11620	All	_
65-33	11621-11632	group-level	_
65-34	11633-11641	analyses	_
65-35	11642-11643	(	_
65-36	11644-11645	1	_
65-37	11646-11649	per	_
65-38	11650-11655	raphe	_
65-39	11656-11663	nucleus	_
65-40	11664-11668	seed	_
65-41	11669-11670	)	_
65-42	11671-11675	were	_
65-43	11676-11685	performed	_
65-44	11686-11691	using	_
65-45	11692-11695	the	_
65-46	11696-11703	general	_
65-47	11704-11710	linear	_
65-48	11711-11716	model	_
65-49	11717-11718	(	_
65-50	11719-11722	GLM	_
65-51	11723-11724	)	_
65-52	11725-11734	framework	_
65-53	11735-11743	provided	_
65-54	11744-11746	in	_
65-55	11747-11750	FSL	_
65-56	11751-11752	’	_
65-57	11753-11754	s	_
65-58	11755-11761	FLAME1	_
65-59	11762-11766	with	_
65-60	11767-11774	outlier	_
65-61	11775-11786	deweighting	_
65-62	11787-11788	.	_

66-1	11789-11791	To	_
66-2	11792-11798	assess	_
66-3	11799-11802	the	_
66-4	11803-11809	effect	_
66-5	11810-11812	of	_
66-6	11813-11820	smoking	_
66-7	11821-11827	status	_
66-8	11828-11830	on	_
66-9	11831-11843	connectivity	_
66-10	11844-11846	of	_
66-11	11847-11850	the	_
66-12	11851-11856	raphe	_
66-13	11857-11863	nuclei	_
66-14	11864-11868	with	_
66-15	11869-11872	the	_
66-16	11873-11884	hippocampal	_
66-17	11885-11892	complex	_
66-18	11893-11894	(	_
66-19	11895-11900	Study	_
66-20	11901-11902	1	_
66-21	11903-11904	)	_
66-22	11905-11906	,	_
66-23	11907-11908	2	_
66-24	11909-11917	separate	_
66-25	11918-11922	GLMs	_
66-26	11923-11924	(	_
66-27	11925-11926	1	_
66-28	11927-11930	per	_
66-29	11931-11936	raphe	_
66-30	11937-11944	nucleus	_
66-31	11945-11949	seed	_
66-32	11950-11951	)	_
66-33	11952-11956	were	_
66-34	11957-11968	constructed	_
66-35	11969-11970	,	_
66-36	11971-11975	with	_
66-37	11976-11977	2	_
66-38	11978-11989	explanatory	_
66-39	11990-11999	variables	_
66-40	12000-12004	each	_
66-41	12005-12006	(	_
66-42	12007-12008	1	_
66-43	12009-12012	per	_
66-44	12013-12018	group	_
66-45	12019-12020	;	_
66-46	12021-12027	smoker	_
66-47	12028-12031	and	_
66-48	12032-12041	nonsmoker	_
66-49	12042-12043	)	_
66-50	12044-12045	.	_

67-1	12046-12051	Group	_
67-2	12052-12063	differences	_
67-3	12064-12068	were	_
67-4	12069-12077	assessed	_
67-5	12078-12080	by	_
67-6	12081-12092	contrasting	_
67-7	12093-12096	the	_
67-8	12097-12106	parameter	_
67-9	12107-12116	estimates	_
67-10	12117-12120	for	_
67-11	12121-12126	these	_
67-12	12127-12128	2	_
67-13	12129-12140	explanatory	_
67-14	12141-12150	variables	_
67-15	12151-12152	.	_

68-1	12153-12155	To	_
68-2	12156-12162	assess	_
68-3	12163-12166	the	_
68-4	12167-12172	acute	_
68-5	12173-12179	effect	_
68-6	12180-12182	of	_
68-7	12183-12190	smoking	_
68-8	12191-12193	on	_
68-9	12194-12206	connectivity	_
68-10	12207-12208	(	_
68-11	12209-12214	Study	_
68-12	12215-12216	2	_
68-13	12217-12218	)	_
68-14	12219-12220	,	_
68-15	12221-12225	pre-	_
68-16	12226-12228	vs	_
68-17	12229-12241	post-smoking	_
68-18	12242-12248	images	_
68-19	12249-12253	were	_
68-20	12254-12261	created	_
68-21	12262-12267	using	_
68-22	12268-12269	a	_
68-23	12270-12275	fixed	_
68-24	12276-12283	effects	_
68-25	12284-12289	model	_
68-26	12290-12292	in	_
68-27	12293-12296	FSL	_
68-28	12297-12298	’	_
68-29	12299-12300	s	_
68-30	12301-12305	FEAT	_
68-31	12306-12307	,	_
68-32	12308-12312	with	_
68-33	12313-12317	each	_
68-34	12318-12322	pre-	_
68-35	12323-12326	and	_
68-36	12327-12339	post-smoking	_
68-37	12340-12345	image	_
68-38	12346-12354	modelled	_
68-39	12355-12359	with	_
68-40	12360-12361	a	_
68-41	12362-12363	1	_
68-42	12364-12367	and	_
68-43	12368-12370	-1	_
68-44	12371-12372	,	_
68-45	12373-12385	respectively	_
68-46	12386-12387	.	_

69-1	12388-12391	The	_
69-2	12392-12401	resulting	_
69-3	12402-12410	contrast	_
69-4	12411-12416	image	_
69-5	12417-12420	for	_
69-6	12421-12425	each	_
69-7	12426-12437	participant	_
69-8	12438-12441	was	_
69-9	12442-12446	then	_
69-10	12447-12456	submitted	_
69-11	12457-12459	to	_
69-12	12460-12461	a	_
69-13	12462-12473	group-level	_
69-14	12474-12482	analysis	_
69-15	12483-12487	that	_
69-16	12488-12497	contained	_
69-17	12498-12501	one	_
69-18	12502-12513	explanatory	_
69-19	12514-12522	variable	_
69-20	12523-12524	,	_
69-21	12525-12533	denoting	_
69-22	12534-12537	the	_
69-23	12538-12543	group	_
69-24	12544-12548	mean	_
69-25	12549-12550	.	_

70-1	12551-12558	Because	_
70-2	12559-12562	the	_
70-3	12563-12573	hypotheses	_
70-4	12574-12580	tested	_
70-5	12581-12590	concerned	_
70-6	12591-12603	connectivity	_
70-7	12604-12606	of	_
70-8	12607-12610	the	_
70-9	12611-12616	raphe	_
70-10	12617-12623	nuclei	_
70-11	12624-12628	with	_
70-12	12629-12632	the	_
70-13	12633-12644	hippocampal	_
70-14	12645-12652	complex	_
70-15	12653-12654	,	_
70-16	12655-12658	all	_
70-17	12659-12670	group-level	_
70-18	12671-12679	analyses	_
70-19	12680-12684	were	_
70-20	12685-12696	constrained	_
70-21	12697-12699	by	_
70-22	12700-12701	a	_
70-23	12702-12713	hippocampal	_
70-24	12714-12721	complex	_
70-25	12722-12726	mask	_
70-26	12727-12731	that	_
70-27	12732-12741	contained	_
70-28	12742-12745	the	_
70-29	12746-12757	hippocampus	_
70-30	12758-12759	,	_
70-31	12760-12775	parahippocampal	_
70-32	12776-12781	gyrus	_
70-33	12782-12783	,	_
70-34	12784-12787	and	_
70-35	12788-12798	entorhinal	_
70-36	12799-12805	cortex	_
70-37	12806-12808	as	_
70-38	12809-12816	defined	_
70-39	12817-12819	by	_
70-40	12820-12823	the	_
70-41	12824-12838	Harvard-Oxford	_
70-42	12839-12844	Atlas	_
70-43	12845-12856	distributed	_
70-44	12857-12863	within	_
70-45	12864-12867	FSL	_
70-46	12868-12869	.	_

71-1	12870-12875	These	_
71-2	12876-12884	analyses	_
71-3	12885-12889	were	_
71-4	12890-12898	followed	_
71-5	12899-12901	by	_
71-6	12902-12913	exploratory	_
71-7	12914-12915	,	_
71-8	12916-12927	whole-brain	_
71-9	12928-12936	analyses	_
71-10	12937-12939	to	_
71-11	12940-12949	determine	_
71-12	12950-12961	selectivity	_
71-13	12962-12964	of	_
71-14	12965-12968	the	_
71-15	12969-12976	effects	_
71-16	12977-12978	(	_
71-17	12979-12982	see	_
71-18	12983-12996	supplementary	_
71-19	12997-13006	Materials	_
71-20	13007-13008	)	_
71-21	13009-13010	.	_

72-1	13011-13014	All	_
72-2	13015-13026	group-level	_
72-3	13027-13038	statistical	_
72-4	13039-13043	maps	_
72-5	13044-13048	were	_
72-6	13049-13066	cluster-corrected	_
72-7	13067-13070	for	_
72-8	13071-13079	multiple	_
72-9	13080-13091	comparisons	_
72-10	13092-13093	(	_
72-11	13094-13099	voxel	_
72-12	13100-13106	height	_
72-13	13107-13116	threshold	_
72-14	13117-13118	:	_
72-15	13119-13120	Z	_
72-16	13121-13122	>	_
72-17	13123-13126	3.1	_
72-18	13127-13128	;	_
72-19	13129-13136	cluster	_
72-20	13137-13149	significance	_
72-21	13150-13151	,	_
72-22	13152-13153	P	_
72-23	13154-13155	<	_
72-24	13156-13159	.05	_
72-25	13160-13161	)	_
72-26	13162-13163	.	_

73-1	13164-13166	To	_
73-2	13167-13174	examine	_
73-3	13175-13178	the	_
73-4	13179-13192	relationships	_
73-5	13193-13195	of	_
73-6	13196-13209	psychological	_
73-7	13210-13220	withdrawal	_
73-8	13221-13224	and	_
73-9	13225-13232	craving	_
73-10	13233-13237	with	_
73-11	13238-13243	group	_
73-12	13244-13255	differences	_
73-13	13256-13258	in	_
73-14	13259-13271	connectivity	_
73-15	13272-13273	(	_
73-16	13274-13279	Study	_
73-17	13280-13281	1	_
73-18	13282-13283	)	_
73-19	13284-13285	,	_
73-20	13286-13288	as	_
73-21	13289-13293	well	_
73-22	13294-13296	as	_
73-23	13297-13301	with	_
73-24	13302-13305	the	_
73-25	13306-13311	acute	_
73-26	13312-13319	effects	_
73-27	13320-13322	of	_
73-28	13323-13330	smoking	_
73-29	13331-13333	on	_
73-30	13334-13346	connectivity	_
73-31	13347-13348	(	_
73-32	13349-13354	Study	_
73-33	13355-13356	2	_
73-34	13357-13358	)	_
73-35	13359-13360	,	_
73-36	13361-13373	connectivity	_
73-37	13374-13380	values	_
73-38	13381-13382	(	_
73-39	13383-13384	z	_
73-40	13385-13391	scores	_
73-41	13392-13393	)	_
73-42	13394-13398	were	_
73-43	13399-13408	extracted	_
73-44	13409-13413	from	_
73-45	13414-13425	significant	_
73-46	13426-13434	clusters	_
73-47	13435-13438	and	_
73-48	13439-13446	entered	_
73-49	13447-13451	into	_
73-50	13452-13455	the	_
73-51	13456-13460	SPSS	_
73-52	13461-13462	(	_
73-53	13463-13467	SPSS	_
73-54	13468-13472	Inc.	_
73-55	13473-13474	)	_
73-56	13475-13478	for	_
73-57	13479-13490	correlation	_
73-58	13491-13495	with	_
73-59	13496-13506	behavioral	_
73-60	13507-13515	measures	_
73-61	13516-13517	.	_

74-1	13518-13529	Association	_
74-2	13530-13532	of	_
74-3	13533-13545	Connectivity	_
74-4	13546-13550	with	_
74-5	13551-13561	Behavioral	_
74-6	13562-13570	Measures	_
74-7	13571-13576	Study	_
74-8	13577-13578	1	_
74-9	13579-13581	To	_
74-10	13582-13586	test	_
74-11	13587-13590	for	_
74-12	13591-13603	associations	_
74-13	13604-13606	of	_
74-14	13607-13619	connectivity	_
74-15	13620-13624	with	_
74-16	13625-13638	psychological	_
74-17	13639-13649	withdrawal	_
74-18	13650-13653	and	_
74-19	13654-13661	craving	_
74-20	13662-13664	in	_
74-21	13665-13672	smokers	_
74-22	13673-13674	,	_
74-23	13675-13681	values	_
74-24	13682-13684	of	_
74-25	13685-13689	mean	_
74-26	13690-13702	connectivity	_
74-27	13703-13704	(	_
74-28	13705-13706	z	_
74-29	13707-13713	scores	_
74-30	13714-13715	)	_
74-31	13716-13720	from	_
74-32	13721-13732	significant	_
74-33	13733-13741	clusters	_
74-34	13742-13746	were	_
74-35	13747-13756	extracted	_
74-36	13757-13760	and	_
74-37	13761-13768	entered	_
74-38	13769-13771	as	_
74-39	13772-13775	one	_
74-40	13776-13782	factor	_
74-41	13783-13784	,	_
74-42	13785-13790	along	_
74-43	13791-13795	with	_
74-44	13796-13799	sex	_
74-45	13800-13801	,	_
74-46	13802-13806	into	_
74-47	13807-13808	2	_
74-48	13809-13817	separate	_
74-49	13818-13832	full-factorial	_
74-50	13833-13839	ANOVAs	_
74-51	13840-13841	,	_
74-52	13842-13844	in	_
74-53	13845-13850	which	_
74-54	13851-13857	scores	_
74-55	13858-13860	on	_
74-56	13861-13864	the	_
74-57	13865-13878	Psychological	_
74-58	13879-13889	Withdrawal	_
74-59	13890-13892	or	_
74-60	13893-13900	Craving	_
74-61	13901-13910	subscales	_
74-62	13911-13915	were	_
74-63	13916-13919	the	_
74-64	13920-13929	dependent	_
74-65	13930-13939	variables	_
74-66	13940-13941	.	_

75-1	13942-13945	Sex	_
75-2	13946-13949	was	_
75-3	13950-13958	included	_
75-4	13959-13961	as	_
75-5	13962-13963	a	_
75-6	13964-13972	separate	_
75-7	13973-13979	factor	_
75-8	13980-13987	because	_
75-9	13988-13990	it	_
75-10	13991-14001	influences	_
75-11	14002-14009	tobacco	_
75-12	14010-14020	withdrawal	_
75-13	14021-14029	symptoms	_
75-14	14030-14031	(	_
75-15	14032-14036	e.g.	_
75-16	14037-14038	,	_
75-17	14039-14040	)	_
75-18	14041-14042	.	_

76-1	14043-14046	All	_
76-2	14047-14055	analyses	_
76-3	14056-14060	were	_
76-4	14061-14070	performed	_
76-5	14071-14073	in	_
76-6	14074-14078	SPSS	_
76-7	14079-14080	.	_

77-1	14081-14091	Bonferroni	_
77-2	14092-14103	corrections	_
77-3	14104-14107	for	_
77-4	14108-14111	all	_
77-5	14112-14124	higher-level	_
77-6	14125-14130	tests	_
77-7	14131-14140	involving	_
77-8	14141-14144	the	_
77-9	14145-14146	2	_
77-10	14147-14152	raphe	_
77-11	14153-14159	nuclei	_
77-12	14160-14164	were	_
77-13	14165-14172	applied	_
77-14	14173-14174	.	_

78-1	14175-14182	However	_
78-2	14183-14184	,	_
78-3	14185-14190	given	_
78-4	14191-14194	the	_
78-5	14195-14199	role	_
78-6	14200-14202	of	_
78-7	14203-14215	serotonergic	_
78-8	14216-14224	function	_
78-9	14225-14227	in	_
78-10	14228-14237	affective	_
78-11	14238-14247	disorders	_
78-12	14248-14249	,	_
78-13	14250-14253	the	_
78-14	14254-14264	hypotheses	_
78-15	14265-14274	primarily	_
78-16	14275-14281	tested	_
78-17	14282-14295	relationships	_
78-18	14296-14303	between	_
78-19	14304-14309	raphe	_
78-20	14310-14316	nuclei	_
78-21	14317-14329	connectivity	_
78-22	14330-14333	and	_
78-23	14334-14347	psychological	_
78-24	14348-14358	withdrawal	_
78-25	14359-14360	;	_
78-26	14361-14374	relationships	_
78-27	14375-14382	between	_
78-28	14383-14395	connectivity	_
78-29	14396-14399	and	_
78-30	14400-14407	craving	_
78-31	14408-14412	were	_
78-32	14413-14424	secondarily	_
78-33	14425-14435	considered	_
78-34	14436-14437	.	_

79-1	14438-14440	As	_
79-2	14441-14445	such	_
79-3	14446-14447	,	_
79-4	14448-14458	Bonferroni	_
79-5	14459-14470	corrections	_
79-6	14471-14474	for	_
79-7	14475-14478	the	_
79-8	14479-14485	number	_
79-9	14486-14488	of	_
79-10	14489-14497	measures	_
79-11	14498-14502	were	_
79-12	14503-14506	not	_
79-13	14507-14516	performed	_
79-14	14517-14518	.	_

80-1	14519-14524	Study	_
80-2	14525-14526	2	_
80-3	14527-14529	To	_
80-4	14530-14534	test	_
80-5	14535-14538	for	_
80-6	14539-14551	associations	_
80-7	14552-14554	of	_
80-8	14555-14568	psychological	_
80-9	14569-14579	withdrawal	_
80-10	14580-14583	and	_
80-11	14584-14591	craving	_
80-12	14592-14596	with	_
80-13	14597-14609	connectivity	_
80-14	14610-14612	of	_
80-15	14613-14616	the	_
80-16	14617-14622	raphe	_
80-17	14623-14629	nuclei	_
80-18	14630-14634	with	_
80-19	14635-14638	the	_
80-20	14639-14650	hippocampal	_
80-21	14651-14658	complex	_
80-22	14659-14665	during	_
80-23	14666-14676	abstinence	_
80-24	14677-14678	,	_
80-25	14679-14680	2	_
80-26	14681-14689	separate	_
80-27	14690-14695	group	_
80-28	14696-14701	level	_
80-29	14702-14710	analyses	_
80-30	14711-14712	(	_
80-31	14713-14716	one	_
80-32	14717-14720	per	_
80-33	14721-14732	self-report	_
80-34	14733-14740	measure	_
80-35	14741-14742	)	_
80-36	14743-14747	were	_
80-37	14748-14757	performed	_
80-38	14758-14763	using	_
80-39	14764-14767	FSL	_
80-40	14768-14769	’	_
80-41	14770-14771	s	_
80-42	14772-14778	FLAME1	_
80-43	14779-14787	modeling	_
80-44	14788-14792	with	_
80-45	14793-14800	outlier	_
80-46	14801-14812	deweighting	_
80-47	14813-14814	;	_
80-48	14815-14820	these	_
80-49	14821-14827	models	_
80-50	14828-14837	contained	_
80-51	14838-14844	either	_
80-52	14845-14858	psychological	_
80-53	14859-14869	withdrawal	_
80-54	14870-14872	or	_
80-55	14873-14880	craving	_
80-56	14881-14887	scores	_
80-57	14888-14890	as	_
80-58	14891-14894	one	_
80-59	14895-14897	EV	_
80-60	14898-14899	.	_

81-1	14900-14905	These	_
81-2	14906-14917	statistical	_
81-3	14918-14922	maps	_
81-4	14923-14927	were	_
81-5	14928-14945	cluster-corrected	_
81-6	14946-14949	for	_
81-7	14950-14958	multiple	_
81-8	14959-14970	comparisons	_
81-9	14971-14972	(	_
81-10	14973-14978	voxel	_
81-11	14979-14985	height	_
81-12	14986-14995	threshold	_
81-13	14996-14997	:	_
81-14	14998-14999	Z	_
81-15	15000-15001	>	_
81-16	15002-15006	3.09	_
81-17	15007-15008	;	_
81-18	15009-15016	cluster	_
81-19	15017-15029	significance	_
81-20	15030-15031	,	_
81-21	15032-15033	P	_
81-22	15034-15035	<	_
81-23	15036-15039	.05	_
81-24	15040-15041	)	_
81-25	15042-15043	.	_

82-1	15044-15046	To	_
82-2	15047-15051	test	_
82-3	15052-15055	for	_
82-4	15056-15068	associations	_
82-5	15069-15076	between	_
82-6	15077-15080	the	_
82-7	15081-15096	smoking-induced	_
82-8	15097-15103	change	_
82-9	15104-15106	in	_
82-10	15107-15119	connectivity	_
82-11	15120-15123	and	_
82-12	15124-15127	the	_
82-13	15128-15134	change	_
82-14	15135-15137	in	_
82-15	15138-15142	both	_
82-16	15143-15156	psychological	_
82-17	15157-15167	withdrawal	_
82-18	15168-15171	and	_
82-19	15172-15179	craving	_
82-20	15180-15181	,	_
82-21	15182-15183	2	_
82-22	15184-15192	separate	_
82-23	15193-15207	full-factorial	_
82-24	15208-15214	ANOVAs	_
82-25	15215-15219	were	_
82-26	15220-15228	employed	_
82-27	15229-15233	with	_
82-28	15234-15240	scores	_
82-29	15241-15243	on	_
82-30	15244-15247	the	_
82-31	15248-15261	psychological	_
82-32	15262-15272	withdrawal	_
82-33	15273-15275	or	_
82-34	15276-15283	craving	_
82-35	15284-15293	subscales	_
82-36	15294-15296	as	_
82-37	15297-15306	dependent	_
82-38	15307-15316	variables	_
82-39	15317-15320	and	_
82-40	15321-15327	values	_
82-41	15328-15330	of	_
82-42	15331-15335	mean	_
82-43	15336-15344	pre-post	_
82-44	15345-15352	smoking	_
82-45	15353-15365	connectivity	_
82-46	15366-15367	(	_
82-47	15368-15369	z	_
82-48	15370-15376	scores	_
82-49	15377-15378	)	_
82-50	15379-15383	from	_
82-51	15384-15395	significant	_
82-52	15396-15404	clusters	_
82-53	15405-15412	entered	_
82-54	15413-15415	as	_
82-55	15416-15419	one	_
82-56	15420-15426	factor	_
82-57	15427-15428	,	_
82-58	15429-15434	along	_
82-59	15435-15439	with	_
82-60	15440-15443	sex	_
82-61	15444-15445	.	_

83-1	15446-15456	Bonferroni	_
83-2	15457-15468	corrections	_
83-3	15469-15472	for	_
83-4	15473-15476	the	_
83-5	15477-15478	2	_
83-6	15479-15484	raphe	_
83-7	15485-15490	seeds	_
83-8	15491-15495	were	_
83-9	15496-15503	applied	_
83-10	15504-15505	.	_

